Vascular Endothelial Growth Factor D, Pulmonary Congestion, and Incidence of Heart Failure
Journal of the American College of Cardiology, 2018
Borné Y., Gränsbo K., Nilsson J., Melander O., Orho-Melander M., Smith J., Engström G.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Pathophysiology Patient Stratification | Plasma |  Olink Target 96 |
Abstract
We hypothesized that VEGF-D could be associated with HF. This hypothesis was explored in a cohort of patients admitted to the
hospital for acute dyspnea and the population-based MDC-CC (Malmö Diet and Cancer Cardiovascular Cohort) study cohort, which has been followed
prospectively for incidence of hospitalizations due to HF. VEGF-D was analyzed in 430 patients admitted to the emergency unit at Skåne University Hospital, Malmö, Sweden, from 2013 to 2014 for symptoms of acute dyspnea. Mean VEGF-D in patients with and without HF was 7.32 0.53 U and 6.80 0.65 U, respectively (p < 0.001). VEGF-D was higher in HF patients with pulmonary congestion (n ¼ 50) on x-ray compared with other HF patients: 7.59 0.38 U versus 7.19 0.55 U (p < 0.001). Our results from patients with acute dyspnea indicate that biomarkers of lymphatic growth could be used to identify subjects with HF from other causes of dyspnea, and potentially enhance rapid diagnostic accuracy in addition to natriuretic peptides.